Last reviewed · How we verify
QLS12010
At a glance
| Generic name | QLS12010 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis (PHASE2)
- A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS12010 CI brief — competitive landscape report
- QLS12010 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI